Hong-Jung Chen Sells Shares of Apollomics, Inc.

Hong-Jung Chen sold 500 shares of Apollomics, Inc. (NasdaqCM: APLM) on June 15, 2026. The transaction was not part of a pre-planned trading program. Apollomics shares were trading at around $13.85 at the time of the sale.

Insider Buying and Selling at Apollomics, Inc.

On June 15, 2026, several insiders at Apollomics made notable transactions. Hong-Jung Chen sold 500 shares without a reported price. On the same day, CEO Hung-Wen Chen bought 5,000 shares, while other insiders like Chu Yi-An and Tsai Hsien-Shu also made transactions. These trades were not planned under Rule 10b5-1 plans.

Other Institutional Activity in Apollomics, Inc.

Citigroup Inc. increased its holdings in Apollomics by 438 shares, resulting in a total of 438 shares worth about $6,811. UBS Group AG also added 78 shares, bringing its total to 142 shares valued at approximately $2,251. On the other hand, Kestra Advisory Services, LLC completely exited its position, selling all 4,380 shares.

Apollomics, Inc. Stock Snapshot

Shares of Apollomics, Inc. (NasdaqCM: APLM) are trading near $13.85. The company has a market cap of around $31.8 million. Its forward P/E ratio is not meaningful since the company is not currently profitable. The stock's 52-week range has been from $3.66 to $42.12. Apollomics has a beta of 1.526, reflecting its volatility relative to the market. The company's current ratio is 0.957, and its quick ratio is 0.911.

Analysts Set New Price Targets

H.C. Wainwright has consistently rated Apollomics as a 'buy', with recent price targets ranging from $2.00 to $17.00 as of May 8, 2024. EF Hutton also maintained a 'buy' rating with a $25.00 price target on May 25, 2023.

About Apollomics, Inc.

Apollomics, Inc. is a biotechnology company based in Foster City, California. It focuses on developing cancer therapies that harness the immune system and target specific molecular pathways. The company is currently conducting clinical trials for several drug candidates, including Vebreltinib and APL-102, aimed at treating various types of cancer. Founded in 2015, Apollomics employs 14 people and is led by CEO Hung-Wen Chen.

Bottom Line

Hong-Jung Chen's sale of Apollomics shares is part of a broader pattern of insider transactions on June 15, 2026. Investors often monitor insider trades for potential insights into a company's prospects. However, it's important to remember that such transactions can occur for many reasons and are not always indicative of the company's future performance.